PRV111 showed a favorable safety profile with no severe adverse events (SAEs).
- PRV111 showed a favorable safety profile with no severe adverse events (SAEs).
- Reported treatment emergent adverse events (TEAEs) were mild or moderate in severity, and no dose-limiting toxicities (DLTs) were observed.
- The clinical trial design was Open-Label, Single-Arm Safety, Tolerability, Anti-Tumor Effects, Systemic Exposure, and Device Technical Effects of PRV111 in subjects with Head and Neck Squamous Cell Carcinoma.
- Squamous cell carcinoma (SCC) is cancer of the squamous cells - thin and flat cells that line the epithelia.